Dear Editor, Tuberculosis (TB) is the most common infectious cause of death and is one among the first ten causes of deaths due to any reason across the globe. [1, 2] It is also the most common cause of death attributed to antimicrobial resistance and among people living with human immunodeficiency virus (HIV) infection. [1] The available global estimates for the year 2016 depict that in excess of 10 million new cases were detected (including 1 million children), while >1.6 million people lost their lives, of which >95% deaths were reported in developing nations. [1, 3] Further, 0.49 million cases of multidrug-resistant TB (MDR-TB) were also detected worldwide, which is again an alarming estimate for the health stakeholders to ponder. [2, 3] Considering the magnitude of the disease, its global distribution, preponderance to affect poor and malnourished people, and the availability of effective first-line drugs, the global leaders have set the target to end the epidemic by 2030. [1, 4] Even though, due to the consistent efforts of the health workers and implementation of effective strategies, the lives of >50 million people have been saved since the start of the century, the incidence of disease is decreasing at about 2% each year, instead of the expected 5%. [3] This clearly reflects that the observed progress is not good enough to ensure that set global targets can be successfully achieved. [1, 3] In other words, despite the commitment of national leaders to end the epidemic, actions and investments are not in accordance with the desired inputs. [3] The analysis of the situation has led to the identification of multiple gaps, which have to be addressed soon. [3] The gaps include underdetection and underreporting, especially in nations with unregulated private sector or weak health-care delivery system. [1] In fact, almost 40% of the estimated cases in the year 2016 were not notified to the health authorities. [3] Furthermore, only 20% of the MDR-TB cases were initiated on treatment, and the treatment success for the same is little above 50%. [3] Further, despite the guideline to put all HIV-TB coinfected patients on antiretroviral therapy, 15% were not initiated. [1, 3] In addition, the chemoprophylaxis for the disease has been recommended for HIV patients and under-five children, but in reality, most of the eligible people are not availing the same. [3] Finally, there is a significant shortage in the financial support to carry out essential disease-related prevention and control activities, and both middle-and low-income nations are paying the price for less financial support. [2, 3] In order to have an effective response against the disease, there is a need to have sustained political action and efforts should be taken to ensure that quality-assured services are accessible to the people who are in maximum need of the same. [2, 4] Moreover, investments are required in the field of disease-related research activities, and health stakeholders should adopt all innovative strategies to improve the existing situation. [4] To conclude, despite making major strides in the field of diagnosis and treatment of TB, there is still a lot needs to be done to improve the reach of the services.
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